In aanvulling op link artikel gepost door Iricos, bijgaand een bericht uit maart 2015, waaruit blijkt dat Genmab geen co-development rights meer had inzake HuMax-TAC-ADC, maar nog wel een 25% ownership. Goed nieuws dus ook voor Genmab.
Genmab will not exercise co-development right, retains 25% ownership of HuMax®-TAC-ADC
Collaboration partner ADC Therapeutics intends to submit IND application for HuMax-TAC-ADC
Copenhagen, Denmark; March 16, 2015 — Genmab A/S (OMX: GEN) announced today it has decided not to exercise the co-development right for HuMax-TAC-ADC under its agreement with ADC Therapeutics Sarl. Genmab will retain 25% of the rights to the product. Under the terms of the companies' agreement, Genmab had a 50% ownership stake with an option to maintain equal ownership of HuMax-TAC-ADC prior to the submission of an Investigational New Drug (IND) application and fund half of the development costs. Genmab has decided not to maintain its co-development right for HuMax-TAC-ADC, but will retain a 25% ownership stake in the product. ADC Therapeutics has indicated it intends to file an IND for HuMax-TAC-ADC in the first half of 2015.
"While we have decided not to fund co-development of HuMax-TAC-ADC with ADC Therapeutics, we are pleased to still have 25% of the rights to the product, which has potential to become a first-in-class antibody-drug conjugate therapeutic in certain hematological cancer indications," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.